Immunotherapy Targeted Therapies Gene Editing Gene Therapy Electromagnetic Therapy CAR T Cell Therapy Flu Prevention Antibody-Drug Conjugates Radioactive Treatment CFTR Modulators Biocompatibility Neuroscience Alpha-Emitting Therapies Oxygen Treatments Regenerative Medicine Music Therapy Combination Therapies Biotechnology Cellular Therapy Combination Treatments Non-invasive Techniques Viral Therapy siRNA Therapy CAR-NK Therapy Genetic Engineering RNA Interference Ultrasound Technology KRAS Inhibitors Cell Therapy Living Medicines Drug Delivery Systems iPSC-derived Therapies Universal CAR-T Therapy Research Institutions Cytokines CAR T-cell Therapy
The consortium commits milestone-based, non-dilutive funding, including about $1.1 million to MiNK, to drive candidates to preclinical nomination.
